Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Ovarian Cancer | Unmet Need | US/EU | 2017

Login to access report north_east
Contact sales account_box

Platinum-based chemotherapy has remained the standard of care for the treatment of platinum-sensitive ovarian cancer, but new classes of drugs such as angiogenesis inhibitors and more recently PARP inhibitors, have entered the therapeutic landscape for this indication. Due to the regulatory approval of targeted therapies, such as Roche/Genentech’s Avastin, AstraZeneca’s Lynparza, Tesaro’s Zejula, and Clovis Oncology’s Rubraca, the market is more crowded leading to higher barriers of entry for emerging therapies in platinum-sensitive ovarian cancer. However, areas of unmet need for the treatment of platinum-sensitive ovarian cancer remain. This content evaluates the key drivers of prescribing and analyzes the areas of significant commercial opportunities that could be valuable commercial opportunities for developers.

Questions Answered:

  • What are the treatment drivers and goals for platinum-sensitive ovarian cancer?
  • What attributes are key influencers, which have limited impact, and which are hidden opportunities?
  • How do current therapies perform on key treatment drivers and goals for platinum-sensitive ovarian cancer?
  • What are the prevailing areas of unmet need and opportunity in platinum-sensitive ovarian cancer?
  • What trade-offs across different clinical attributes and price are acceptable to U.S. and European medical oncologists for a hypothetical new therapy for platinum-sensitive ovarian cancer?

Markets covered: United States, United Kingdom, France, and Germany.

Primary research: Survey of 61 U.S. and 30 European medical oncologists fielded in April 2017.

Key companies: Roche/Genentech, AstraZeneca, Tesaro, Clovis Oncology.

Key drugs: Carboplatin/Paclitaxel, Avastin, Lynparza, Zejula, Rubraca.

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Axial Spondyloarthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Ankylosing Spondylitis (US)
Ankylosing spondylitis (AS) is a chronic inflammatory disease that primarily affects the sacroiliac joints and the axial skeleton, leading to persistent back pain and stiffness. The main treatment…
north_east
Report
Alopecia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Alopecia Areata (US)
Alopecia areata (AA) is an autoimmune condition in which the immune-mediated damage to hair follicles results in patchy or extensive hair loss. AA treatment is evolving rapidly as dermatologists…
north_east
Report
Immune Thrombocytopenic Purpura – Current treatment – Treatment Algorithms: Claims Data Analysis – Immune Thrombocytopenic Purpura (US)
Immune thrombocytopenic purpura (ITP) is an autoimmune disorder characterized by a low platelet count, resulting in an increased risk of bleeding. Current therapies for ITP can be largely divided…
north_east
Report
Myasthenia Gravis – Geography Focus: China – China In-Depth: Myasthenia Gravis
China’s myasthenia gravis (MG) market is transitioning from long-standing symptomatic regimens toward a more structured mix of targeted therapies that increasingly shape treatment pathways…
north_east
Report
Chronic Urticaria – Current Treatment – Treatment Algorithms: Claims Data Analysis – Chronic Spontaneous Urticaria (US)
The treatment landscape for chronic spontaneous urticaria (CSU) remains largely driven by oral therapies, including approved antihistamines and off-label agents such as DMARDs and…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east